LXEO · Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics' Q4 and full year 2025 results highlight significant progress across its cardiac gene therapy pipeline alongside disciplined cost management. For full year 2025, R&D expenses declined 13.9% year-over-year to $63.8 million, driven by efficiencies in clinical trial execution, while G&A expenses rose 43.5% to $45.5 million due to investments in leadership and commercial readiness infrastructure. Full year net loss widened slightly to $100.0 million, or $1.86 per share, from $98.3 million, or $3.09 per share in 2024, with the per-share improvement driven by the October 2025 $154 million equity financing that increased outstanding share count. Management noted the $246.6 million cash position as of December 31, 2025 is sufficient to fund operations into 2028, eliminating near-term liquidity risk as the company advances its lead candidate LX2006 into the pivotal SUNRISE-FA 2 trial in 1H 2026. The recent FDA CDRP meeting alignment on flexible CMC validation for LX2006 reduces regulatory risk for the BLA submission, while the Johnson & Johnson collaboration validates the company's AAV gene therapy delivery technology. The appointment of Narinder Bhalla as CMO strengthens the team's late-stage clinical and regulatory expertise ahead of planned pivotal trial execution for LX2006 and upcoming LX2020 data readouts in Q4 2026.